SCHEMBL273252

SCHEMBL273252

COC(=O)c1ccc2c(CCN)c[nH]c2c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.78
HTR2A P28223 4/20 0.60
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
HTR1A P08908 4/20 0.58
HTR1B P28222 4/20 0.58
HTR1D P28221 3/20 0.58
HTR2C P28335 4/20 0.57
GPR84 Q9NQS5 1/20 0.56
HTR7 P34969 4/20 0.56
HTR6 P50406 3/20 0.56
CYP1A2 P05177 2/20 0.56
TSHR P16473 2/20 0.56
HTR5A P47898 2/20 0.56
HSD17B10 Q99714 1/20 0.56
CDK2 P24941 1/20 0.52
ASH1L Q9NR48 1/20 0.51
MAPT P10636 1/20 0.50
NFKB1 P19838 1/20 0.50
HTR4 Q13639 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2534004 0.89 HTR1A (0.73) NPC1HTR2AMEN1KMT2AHTR1A
SCHEMBL7424745 0.88 NPC1 (0.80) NPC1MEN1KMT2AGPR84CDK2
SCHEMBL2533737 0.87 NPC1 (0.60) NPC1HTR2AMEN1KMT2AHTR1A
SCHEMBL5129036 0.86 NPC1 (0.77) NPC1MEN1KMT2AGPR84CDK2
SCHEMBL7415036 0.85 NPC1 (0.76) NPC1MEN1KMT2AGPR84CDK2
SCHEMBL7423854 0.85 NPC1 (0.76) NPC1MEN1KMT2AGPR84CDK2
SCHEMBL10981015 0.83 NPC1 (0.73) NPC1MEN1KMT2AHTR1AHTR1B
SCHEMBL10982062 0.83 NPC1 (0.73) NPC1MEN1KMT2AHTR1AHTR1B
SCHEMBL8804872 0.83 NPC1 (0.73) NPC1MEN1KMT2AGPR84CDK2
SCHEMBL10987953 0.83 NPC1 (0.73) NPC1MEN1KMT2AHTR1AHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108727370-A The tetrahydro-beta-carboline micromolecular organic compound and its derivative and medical usage of a kind of hydroxyl substitution 华东师范大学 2018-11-02 CN disclosed
US-8524704-B2 Azepinoindole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2013-09-03 US disclosed
US-8133992-B2 Azepinoindole and pyridoindole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2012-03-13 US disclosed
EP-1532153-B1 AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS X CEPTOR THERAPEUTICS INC (US) 2012-02-29 EP disclosed
US-20100173824-A1 Azepinoindole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2010-07-08 US disclosed
US-20090326218-A1 Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents EXELIXIS, INC. (US) 2009-12-31 US disclosed
US-7595311-B2 Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents EXELIXIS, INC. (US) 2009-09-29 US disclosed
US-7485634-B2 Azepinoindole and pyridoindole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2009-02-03 US disclosed
EP-1692136-A2 AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS X-Ceptor Therapeutics, Inc. (US) 2006-08-23 EP disclosed
WO-2005056554-A2 AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2005-06-23 WO disclosed
EP-1532153-A1 AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS X-Ceptor Therapeutics, Inc. (US) 2005-05-25 EP disclosed
US-20050054634-A1 Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents AKARNA THERAPEUTICS, LTD. (GB) 2005-03-10 US disclosed
US-20040023947-A1 Azepinoindole and pyridoindole derivatives as pharmaceutical agents X-CEPTOR THERAPEUTICS INC. 2004-02-05 US disclosed
WO-2003099821-A1 AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS X-CEPTOR THERAPEUTICS, INC. (US) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023947-A1 Azepinoindole and pyridoindole derivatives as pharmaceutical agents HTR5A, MTNR1A, PTGDR NPC1 1969/4885HTR2A 10/4885MEN1 2235/4885
US-20100173824-A1 Azepinoindole Derivatives As Pharmaceutical Agents HTR2A, HTR5A, HTR2C NPC1 864/4885HTR2A 1/4885MEN1 2447/4885
US-20090326218-A1 Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents HTR5A, MTNR1A, PTGDR NPC1 1969/4885HTR2A 10/4885MEN1 2235/4885
US-20050054634-A1 Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents GPR119, IRS1, INSR NPC1 1345/4885HTR2A 309/4885MEN1 4114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.